Objective-We sought to characterize associations between aminotransferase levels and cardiometabolic risk after accounting for visceral adipose tissue and insulin resistance. Methods and Results-Participants (n=2621) from the Framingham Heart Study (mean age 51, 49.8% women) were included. Sex-specific linear and logistic regressions were used to evaluate associations between aminotransferase levels and cardiometabolic risk factors. In multivariable models, increased alanine aminotransferase levels were associated with elevated blood pressure, fasting plasma glucose, and triglycerides and lower high-density lipoprotein levels (all P≤0.007). Furthermore, each 1-SD increase in alanine aminotransferase corresponded to an increased odds of hypertension, diabetes mellitus, the metabolic syndrome, impaired fasting glucose, and insulin resistance estimated by the homeostasis model assessment of insulin resistance (odds ratio, 1.29-1.85, all P≤0.002). Associations with alanine aminotransferase persisted after additional adjustment for visceral adipose tissue, insulin resistance, and body mass index with the exception of high-density lipoprotein cholesterol in both sexes and blood pressure in women. Results were materially unchanged when moderate drinkers were excluded, when the sample was restricted to those with alanine aminotransferase <40 U/L, and when the sample was restricted to those without diabetes mellitus. Similar trends were observed for aspartate aminotransferase levels, but associations were more modest. 
N onalcoholic fatty liver disease (NAFLD) is increasingly recognized as the hepatic manifestation of obesity and its metabolic and cardiovascular sequelae. 1, 2 Serum aminotransferase levels, particularly alanine aminotransferase (ALT), may be used to estimate NAFLD in obese and nonobese individuals, 3, 4 and serum ALT appears to be the liver enzyme most closely related to liver fat content. 5 Elevated ALT levels have been associated with metabolic risk factors for cardiovascular disease (CVD), including type 2 diabetes mellitus and the metabolic syndrome. [6] [7] [8] [9] Such associations raise the possibility that NAFLD, obesity, and metabolic derangements may share a common pathogenesis. They also raise the possibility that serum aminotransferase levels may be useful indicators of cardiometabolic risk above and beyond adiposity and insulin resistance (IR).
The goal of the present study was to explore the association between serum aminotransferase levels and metabolic risk factors for CVD in a community-based sample unselected for NAFLD, obesity, or metabolic disease. We tested the hypothesis that aminotransferase levels are associated with cardiometabolic risk above and beyond generalized and central adiposity and IR. We also tested this hypothesis among those with both elevated and normal aminotransferase levels.
Methods

Study Sample
Subjects were drawn from the Framingham Heart Study, a prospective cohort study that began with 5209 residents of Framingham, Massachusetts in 1948. In 1971, the offspring and spouses of the original cohort were enrolled in the Offspring Study, and in 2002 the children of the original cohort's offspring were enrolled in the Third Generation Study. Between June 2002 and April 2005, 3529 offspring and third generation participants were enrolled in the Multi-Detector Computed Tomography substudy and underwent chest and abdominal computed tomographic (CT) scanning. The current study sample consisted of the 2621 participants (1305 women and 1316 men) who had interpretable abdominal CT scans and a complete covariate profile. The institutional review boards of the Boston University Medical Center and Massachusetts General Hospital approved the study protocol. All subjects provided informed written consent.
Multidetector CT Scan Protocol and Measurement of Visceral Adipose Tissue and Subcutaneous Adipose Tissue
Participants underwent 8-slice multidetector abdominal CT scanning in a supine position (LightSpeed Ultra, General Electric, Milwaukee, WI). Twenty-five contiguous 5-mm-thick slices (120 kVp, 400 mA, gantry rotation time 500 ms, and table feed 3:1) were obtained, covering 125 mm above the level of S1. Visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT) volumes were quantified from CT scans using a semiautomatic segmentation technique at a dedicated offline workstation (Aquarius 3D Workstation; TeraRecon, San Mateo, CA). A reader manually traced the abdominal muscular wall separating the 2 layers. An image display window width of −195 to −45 Hounsfield units and a window center of −120 Hounsfield units were used to identify pixels containing fat. VAT was defined as adipose tissue inside the abdominal muscular wall and SAT as adipose tissue outside the abdominal muscular wall. Interclass correlations for inter-reader comparisons were 0.997 for SAT and 0.992 for VAT on a random sample of 100 scans; high intrareader correlations were similarly obtained.
Baseline Measurements and Definitions
Serum ALT and aspartate aminotransferase (AST) levels were measured on fasting morning samples using the kinetic method (Beckman Liquid-Stat Reagent Kit). 10 Coefficients of variation were 4.1% to 4.4% and 3.8% to 4.5% for ALT and AST, respectively.
Covariates and Risk Factor Assessment
Risk factors used in this study were measured at the seventh Framingham Offspring examination (1998) (1999) (2000) (2001) and the first Third Generation examination (2002) (2003) (2004) (2005) . Body mass index (BMI) was calculated as weight in kilograms divided by the square of height in meters. Waist circumference was measured at the umbilicus. Serum triglycerides, high-density lipoprotein (HDL) cholesterol, and fasting plasma glucose were measured in fasting morning samples from participants. Diabetes mellitus was defined as fasting plasma glucose ≥126 mg/dL or treatment with a hypoglycemic agent or insulin; impaired fasting glucose was defined as a fasting plasma glucose level of 100 to 125 mg/dL in the absence of diabetes mellitus treatment. Hypertension was defined as systolic blood pressure (SBP) ≥140 mm Hg and diastolic blood pressure (DBP) as ≥90 mm Hg or antihypertensive treatment. Current smoking was defined as smoking ≥1 cigarette per day in the past year. Alcohol use was evaluated through a physician-administered questionnaire, and patients were considered to have high alcohol intake if they reported more than 14 drinks per week (men) or 7 drinks per week (women). Women were classified as postmenopausal if periods had stopped for ≥1 year. Metabolic syndrome was defined by modified Adult Treatment Panel III criteria (impaired fasting glucose defined as fasting plasma glucose 100-125 mg/dL in the absence of treatment of diabetes mellitus, the high triglyceride component was defined as triglycerides ≥150 mg/dL or treatment with a lipid-lowering agent, and blood pressure criteria were modified to include treatment for hypertension). IR was defined as having greater than the top quartile of the homeostasis model assessment of insulin resistance (HOMA-IR; fasting glucose × fasting insulin/22.5) distribution among individuals without diabetes mellitus by sex 11 (for the analysis sample, >3.06 for women and >3.51 for men).
Statistical Analysis
ALT and AST were natural log-transformed to normalize their skewed distribution. Sex-specific, age-adjusted Pearson correlations between log ALT and log AST levels were calculated with adiposity traits and cardiometabolic risk factors.
Multivariable linear and logistic regression models were used to assess the significance of covariate-adjusted associations between aminotransferase levels and continuous and dichotomous cardiometabolic risk factors, respectively. The increment in covariate-adjusted risk factors per 1-SD increase in log ALT and log AST was estimated for continuous variables, whereas the odds ratio (OR) of the risk factor per 1-SD increase in log aminotransferase level was estimated for dichotomous variables. Covariates included age, current smoking, high alcohol intake (>14 drinks/wk for men or >7 drinks/wk for women), physical activity, menopausal status (women only), and hormone replacement therapy (women only). For models of SBP and DBP, fasting plasma glucose, HDL cholesterol, and log triglycerides, an additional covariate of treatment for hypertension, diabetes mellitus, or lipid disorders, respectively, was included. Finally, additional models evaluated the impact of the associations after additional adjustment for VAT, HOMA-IR (where appropriate), and BMI (separately).
In secondary analyses, we restricted the sample to those with aminotransferase levels in the normal range (ALT<40 U/L or AST<40 U/L, respectively), to participants not reporting high alcohol intake (≤7 drinks per week [women] or ≤14 drinks per week [men]), and to individuals without diabetes mellitus.
Furthermore, age-adjusted rates of CVD risk factors were calculated within tertiles of ALT stratified by tertiles of VAT and a test of trend (also age-adjusted) across ALT tertile levels within each VAT tertile was performed. Given the greater number and strength of associations between ALT and cardiometabolic risk factors than between AST and cardiometabolic risk factors, the analysis was only performed with ALT. SAS version 9.2 was used to perform all computations. A 2-tailed P value <0.05 was considered significant.
Results
Study Sample Characteristics
The characteristics of the study sample are summarized in Table 1 . The mean age of study participants was 52 years for women and 50 years for men; 49.8% of participants were women. Mean ALT and AST levels were 20. 
Correlations Between Aminotransferase Levels and Cardiometabolic Risk Factors
Increasing log ALT levels were associated with most cardiometabolic risk factor levels in women and men after adjusting for age (Table 2 ). More specifically, higher levels of log ALT were associated with higher levels of SAT, VAT, waist circumference, BMI, log triglycerides, serum fasting glucose, IR, SBP and DBP, and with lower HDL cholesterol. Correlations between log AST and risk factors showed similar trends as observed in ALT, but associations were attenuated and fewer significant correlations were observed. Higher log AST levels were correlated with higher DBP, and greater IR in men and women and additionally with increased BMI, waist circumference, SBP, and VAT in men.
Multivariable-Adjusted Models
In multivariable-adjusted models, log ALT levels were associated with SBP and DBP in both sexes. Among women, SBP was on average 1.19 mm Hg higher per 1-SD increase in log ALT (P=0.007) and among men, SBP was 2.07 mm Hg higher on average per 1-SD increase in log ALT (P<0.0001), after covariate adjustment. This association was attenuated slightly but persisted in men after additional adjustment for VAT, IR, and BMI (separately) and persisted in women after adjustment for IR, but significance was lost after adjustment for VAT and for BMI. Associations between DBP and log ALT levels remained significant in both sexes after adjustments for VAT, IR, and BMI (Table 3) .
Fasting plasma glucose was associated with ALT level in both men and women; these associations persisted after additional adjustments for VAT, IR, and BMI.
For each 1-SD increase in log ALT, HDL was 1.4 mg/ dL lower in women (P=0.001) and 1.1 mg/dL lower in men (P=0.002); however, these associations did not persist after additional adjustment for VAT, IR, or BMI. For each 1-SD increase in log ALT, log triglycerides were 0.08 mg/dL higher in women (P<0.0001) and 0.12 mg/dL higher in men (P<0.0001). These associations remained significant with slight attenuation in both sexes after adjustment for VAT, IR, and BMI.
Associations between log ALT and dichotomous traits were fairly strong (all OR >1.29, all P≤0.0002) and generally persisted after adjustment for VAT, BMI, and HOMA-IR. For example, for every 1-SD increase in log ALT, the OR of metabolic syndrome was 1.61 times higher in women and 1.72 times higher in men. These relations remained significant after adjustment for VAT, IR, and BMI.
Far fewer significant associations were observed between log AST and cardiometabolic risk factors than between log ALT and risk factors (Table 4) . Of the risk factors tested, only DBP and HDL were significantly associated with AST level in both men and women before and after additional adjustments for VAT, IR, and BMI.
Associations between ALT and AST and cardiometabolic risk factors were generally similar between men and women, and sex interactions were generally negative (Tables 3 and 4) .
Secondary Analyses
Secondary analyses excluded participants with high alcohol intake (>7 drinks per week [women], >14 drinks per week [men], n=394), participants with diabetes mellitus (n=159), and participants with ALT levels above the normal range (≥40 U/L, n=322), respectively. When moderate drinkers were excluded from the analysis, results were essentially unchanged (data not shown). Among individuals without diabetes mellitus, there was attenuation of the effect size of the association between log ALT and fasting glucose level (beta coefficient 1.79 to 1. MV indicates multivariable; OR, odds ratio; VAT, visceral adipose tissue; HOMA-IR, homeostasis model of insulin resistance; BMI, body mass index; HDL, high-density lipoprotein; and IFG, impaired fasting glucose. Data presented include effect size (SE) expressed per 1-SD increase in log alanine aminotransferase (ALT) for continuous data, and the odds of the condition per 1-SD increase in log ALT with 95% CI for dichotomous data.
*Adjusted for age, current smoking, high alcohol intake, physical activity, and menopausal status (women only), hormone replacement therapy (women only); for blood pressure, FPG, fasting plasma glucose; HDL cholesterol, and log triglycerides, an additional covariate of treatment for hypertension (HTN), diabetes mellitus, or lipid disorders, respectively, was included. MV indicates multivariable; OR, odds ratio; VAT, visceral adipose tissue; HOMA-IR, homeostasis model of insulin resistance; BMI, body mass index; HDL, high-density lipoprotein; and IFG, impaired fasting glucose. Data presented include effect size (SE) expressed per 1-SD increase in log AST for continuous data, and the odds of the condition per 1-SD increase in log aspartate aminotransferase with 95% CIs for dichotomous data.
*Adjusted for age, current smoking, high alcohol intake, physical activity, and menopausal status (women only), hormone replacement therapy (women only); for blood pressure, FPG, HDL cholesterol, and log triglycerides, an additional covariate of treatment for HTN, diabetes mellitus, or lipid disorders, respectively, was included.
VAT, IR, and BMI (data not shown). When multivariable and logistic regressions were simultaneously adjusted for BMI, VAT, and HOMA-IR (with the exception of glycemic traits, which were not adjusted for HOMA-IR, and HOMA-IR, which was not adjusted for glucose), results were not appreciably different (data not shown).
When the sample was limited to those with ALT levels in the normal range (<40 U/L), significant associations persisted without attenuation of effect size (Table in the online-only Data Supplement). Of note, the odds of impaired fasting glucose were similar for each 1-SD increase in log ALT for both men and women in the normal range ALT sample (OR, ). These associations persisted after additional adjustment for VAT and BMI. Among women with ALT in the normal range, the odds of the metabolic syndrome per 1-SD increase in log ALT were increased relative to the entire sample (OR, 1.78; P<0.0001 versus OR, 1.61; P<0.0001). This relationship remained after adjustment for VAT, IR, and BMI. Among men with ALT in the normal range, the effect sizes of each 1-SD increase in log ALT on SBP and DBP were increased relative to the entire sample.
Combination of Log ALT and VAT
Age-adjusted rates of cardiometabolic risk factors within tertiles of ALT stratified by tertiles of VAT are shown in the Figure. In women and men, the age-adjusted prevalence of diabetes mellitus, impaired fasting glucose, hypertension, and metabolic syndrome increased across increasing tertiles of VAT. Of note, rates of these risk factors also increased across increasing ALT tertiles in the higher VAT tertiles for both sexes.
Discussion Principal Findings
Our results demonstrate a robust association between serum ALT levels and multiple cardiometabolic risk factors in a community-based sample. The most important finding in our study is the strong association between serum ALT level and cardiometabolic risk after adjustment for VAT and IR. These associations remained significant when participants reporting moderate alcohol intake (>7 drinks per week [women], >14 drinks per week [men] ) and those with diabetes mellitus were excluded from the analysis. In addition, among those with serum ALT in the normal range (<40 U/L), the associations of log ALT and cardiometabolic risk factors remained significant after multivariable adjustment. These findings suggest that serum ALT levels are associated with cardiometabolic risk independent of visceral adiposity and IR and that even modest elevations in ALT that fall in the normal range may be a clinically significant precursor to cardiometabolic disease.
In the Context of Current Literature
Multiple studies have linked NAFLD with metabolic risk factors for CVD, including type 2 diabetes mellitus and the metabolic syndrome, in a variety of populations.
6-9,12,13 The majority of individuals with NAFLD are overweight or obese or have type 2 diabetes mellitus, but NAFLD is associated with IR in normal weight individuals without diabetes mellitus.
14 This suggests that NAFLD may be an early predictor of metabolic disease that is distinct from other adiposity traits. Many studies have adjusted for easily measurable adiposity traits such as waist circumference and BMI. In a small study of male subjects, Targher et al 15 found that nonalcoholic steatohepatitis was predictive of an atherogenic biomarker profile independent of visceral adiposity, as measured by ultrasound. This finding suggests that fat in the liver may confer CVD risk beyond that associated with more generalized obesity. Previous work from the Framingham Heart Study found that fatty liver as measured by CT is associated with lipid and glucose traits independent of VAT. 16 Our results extend these findings to show that serum ALT levels, as surrogate biomarkers of NAFLD, are also associated with cardiometabolic risk factors independent of VAT. In addition, we show that ALT levels are associated with metabolic risk independent of BMI and IR.
Many studies using aminotransferase levels to examine the link between NAFLD and cardiometabolic risk have considered 40 U/L as the upper limit of normal for both ALT and AST. These values were derived from the mean+2 SD in a healthy referent sample from the 1950s. 17 More recently, some have issued calls to adjust normal ALT values on the basis of sex and BMI. 18, 19 Prati et al 20 found that lowering the upper limit of normal ALT levels to 30 U/L in men and 19 U/L in women would increase the sensitivity of liver injury detection from 55% to 76%, mostly because of increased detection of fatty liver. The presence of histological damage from NAFLD in the context of normal ALT levels has also been observed. 21, 22 Our finding that serum ALT levels <40 U/L are strongly associated with cardiometabolic risk suggests that ALT levels represent a continuum of risk rather than a cutoff below which can be considered healthy and that even subtle ALT elevations may be clinically relevant.
Potential Mechanisms
There are several possible mechanisms linking NAFLD, nonalcoholic steatohepatitis, and cardiometabolic risk. A 2-hit hypothesis of lipid accumulation in hepatocytes in the presence of hepatic IR and has been proposed to explain the development of NAFLD and nonalcoholic steatohepatitis. 23 Intrahepatic fatty acid accumulation results mostly from the lipolysis of abdominal adipose tissue, but also from dietary chylomicrons and de novo lipogenesis in the liver. 24, 25 The relative contributions of fat in the liver versus other fat depots to cardiometabolic risk are not entirely clear. Previous work from the Framingham Heart Study found that both fatty liver and VAT are associated with cardiometabolic risk. 16, 26 Fabbrini et al 27 found that fatty liver, but not VAT, is associated with metabolic abnormalities, whereas work from the Jackson Heart Study found that fatty liver and VAT were independently associated with cardiometabolic risk, but that associations with triglycerides and HDL cholesterol were stronger for VAT than fatty liver. 28 Secretion by adipose tissue of adipokines, such as adiponectin, leptin, and resistin, may play a role in the development of NAFLD and other cardiometabolic abnormalities. [29] [30] [31] For example, patients with NAFLD have reduced levels of adiponectin, 32 a hormone with anti-inflammatory and antifibrotic properties, lower levels of which have been associated with cardiometabolic risk. 33, 34 In addition, the liver is the site of production for biomarkers of inflammation and endothelial dysfunction, including C-reactive protein, fibrinogen, and plasminogen activator inhibitor-1, all of which are elevated in fatty liver disease and which are considered biomarkers of CVD risk. 15, 31 Our findings showed a greater number and strength of associations between ALT and cardiometabolic risk factors than between AST and cardiometabolic risk factors. This is likely attributable to the stronger association of ALT with NAFLD 35 and obesity. 36 It may also reflect the greater specificity of ALT for liver injury because ALT is restricted to hepatocytes, whereas AST is also released from the heart, skeletal muscle, kidney, brain, pancreas, and red blood cells.
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Strengths and Limitations
Compared with previous work on aminotransferase levels and cardiometabolic risk, the strengths of the present study include a large population-based sample not selected for NAFLD, obesity, or metabolic disease with rich covariate data, including VAT. The richness of the covariate data allows us to adjust for several important confounders in exploring the association between aminotransferase levels and cardiometabolic risk and to further adjust for visceral adiposity and IR. We were able to conduct these analyses in a sample that included participants with normal and elevated aminotransferase levels.
Some limitations deserve mention. First, this study is cross-sectional and observational, so we are unable to assess temporality and causality. Second, we relied on a single measurement of aminotransferase levels for each participant, so we were unable to account for interindividual variation in these levels. Such variability, however, is likely to bias our results toward the null hypothesis, and is unlikely to account for our significant findings. We were also unable to exclude individuals with non-NAFLD liver disease such as viral hepatitis or drug-induced liver injury as the cause of aminotransferase elevations, although the absolute numbers of such conditions are likely to be low in our community-based population study. We were unable to separate the retroperitoneal VAT compartment in our analyses. Waist circumference measured at the umbilicus can be problematic in those with a pendulant abdomen. Participants taking metformin were classified as having diabetes mellitus, although they might have been taking the medication for other reasons. We made use of surrogate markers for both IR using the HOMA-IR and NAFLD using serum aminotransferase levels, which are insensitive for detecting NAFLD, nonalcoholic steatohepatitis, advanced fibrosis, and cirrhosis. Finally, our sample comprised whites, which limits the generalizability of our results to other populations or ethnic groups.
Conclusions
Serum ALT levels, including those in the normal range, are associated with cardiometabolic risk above and beyond visceral fat and IR.
Figure.
Age-adjusted prevalence of diabetes mellitus, impaired fasting glucose (IFG), hypertension, and metabolic syndrome by tertiles of alanine aminotransferase (ALT) within tertiles of visceral adipose tissue (VAT). Results are shown for women (top) and men (bottom). Significant P values for trend across ALT tertiles within each VAT tertile are designated by *P<0.05, **P<0.01, ***P<0.001.
